Vivo Capital
MLTX icon

Vivo Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Vivo Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16.4M Hold
1,400,000
– – 1.8% 22
2026
Q2 		$27.3M Buy
1,400,000
+400,000
+40% +$7.25M 2.49% 17
2026
Q1 		$18.6M Hold
1,000,000
– – 1.55% 24
2025
Q4 		$13.2M Buy
+1,000,000
New +$11.8M 0.85% 31

Other funds holding MLTX

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Jump Financial
Jump Financial Chicago, Illinois $13.9B AUM 45.06% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Vivo Capital's MLTX Position: Q3 2026 in Review

Vivo Capital held its MoonLake Immunotherapeutics (MLTX) position steady in Q3 2026 at 1,400,000 shares worth $16.4M. The position accounts for 1.8% of the portfolio, ranked #22.

Vivo Capital first reported a position in MLTX in Q4 2025 and has held it in 4 quarters since. The position peaked at $27.3M in Q2 2026. 106 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Vivo Capital held 1,400,000 shares of MoonLake Immunotherapeutics worth $16.4M as of Q3 2026.
  • Vivo Capital left its MoonLake Immunotherapeutics share count unchanged in Q3 2026.
  • MoonLake Immunotherapeutics made up 1.8% of Vivo Capital's portfolio in Q3 2026, its #22 holding.
  • Vivo Capital first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 4 quarters since.
  • Vivo Capital's MoonLake Immunotherapeutics position peaked at $27.3M in Q2 2026.
  • 106 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.